| Code | CSB-RA017647MB3HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Evolocumab, designed to specifically bind to proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 is a secreted serine protease that plays a critical role in cholesterol homeostasis by binding to low-density lipoprotein receptors (LDLR) on hepatocyte surfaces, promoting their degradation and preventing receptor recycling. By reducing LDLR availability, elevated PCSK9 levels lead to increased circulating LDL cholesterol, a major risk factor for atherosclerotic cardiovascular disease, familial hypercholesterolemia, and coronary artery disease.
Evolocumab is a fully humanized IgG2 monoclonal antibody that inhibits PCSK9 function by preventing its interaction with LDLR, thereby preserving receptor expression and enhancing LDL clearance from the bloodstream. This biosimilar antibody provides researchers with a valuable tool for investigating PCSK9 biology, lipid metabolism pathways, cardiovascular disease mechanisms, and therapeutic antibody development. It supports studies examining cholesterol regulation, receptor-mediated endocytosis, and the molecular basis of lipid disorders.
There are currently no reviews for this product.